Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers with a strong start to fiscal year 2022; outlook raised
Press release

Siemens Healthineers with a strong start to fiscal year 2022; outlook raised

Siemens Healthineers AG today announced its results for the fiscal year 2022 first quarter that ended December 31, 2021.

Published on February 3, 2022

Q1 Fiscal Year 2022

  • Very good growth: comparable revenue growth of 9.5% and equipment book-to-bill ratio at 1.20
  • Diagnostics revenue with excellent comparable growth of 19.7%, including €329 million from rapid COVID-19 antigen tests
  • Very solid start for Varian with revenue contribution of €750 million
  • Imaging continues to be strong with 5.9% comparable revenue growth; Advanced Therapies with 3.3%
  • Adjusted EBIT margin of 17.6% – reflecting negative currency effects, currently higher procurement and logistics costs, and a positive impact from higher contributions from rapid antigen tests
  • Adjusted basic earnings per share up 12% to €0.55
  • Continued strong free cash flow of €556 million

Updated Outlook for Fiscal Year 2022

Due to the increased demand for rapid COVID-19 antigen tests in Europe and the approval of our rapid antigen tests in the U.S., we raise our outlook for fiscal year 2022. The outlook is now based on the assumption that the Diagnostics segment will generate around €700 million (previously: around €200 million) in revenue with rapid COVID-19 antigen tests. As a result, we now expect comparable revenue growth between 3% and 5% (previously: 0% to 2%) and adjusted basic earnings per share between €2.18 and €2.30 (previously: €2.08 to €2.20).

Bernd Montag, CEO of Siemens Healthineers AG:

»Our team delivered a strong start for the next phase of our company despite a more than challenging environment. It is a great proof point of our ambition to further accelerate growth and make an even greater impact on global healthcare. Additional upside from our rapid antigen testing allows us to raise our full year outlook.«

Download Quarterly Statement(pdf, 313.80 KB)

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.